Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Panelists discuss how payers seek good return on investment when evaluating expensive gene therapies, creating potential friction when innovative treatments come at significant costs, requiring ...

Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at ...

Air pollution exposure, both before and after birth, significantly escalates the risk of respiratory infections in children.

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic ...

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting ...

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for ...